Home » Newsletters » BioWorld Science

BioWorld Science

May 23, 2012

View Archived Issues

Phase I/II and phase II gene therapy trials conducted in patients with SCID

S1P1 receptor agonist shows efficacy in preclinical models of IBD

French researchers present new HSP 90 inhibitors

Eisai presents highlights of fiscal 2011

Novel candidate analgesic patented

Early clinical results presented for tralokinumab in asthma

A new small molecule inhibits dermal inflammation in mouse models

Human pharmacokinetic profile of RO-5458640 determined in monkeys

BMS investigators describe preclinical studies with antimigraine candidate

Phase I/II Xerecept results promising in children with cerebral tumors

Research at Presidio Pharmaceuticals yields new HCV inhibitors

U.S. government supports phase III smallpox vaccine study

Karolinska University Hospital and GE Healthcare enter research collaboration

Phase III HA-irinotecan study to continue enrollment

Novel imaging agents created to diagnose Alzheimer's disease

New AP-TNAP inhibitors presented in France

Catalyst reports topline data from phase Ia CPP-115 study

Unigene reports encouraging preclinical data on UGP-281

Novel ER-alpha agonists patented

FDA approves expanded use of Levemir

Chelsea Therapeutics discusses Northera complete response letter with FDA

Repros submits revised documentation to FDA for Androxal studies

NICE publishes guidance on rivaroxaban

Adva-27a shows superior pharmacokinetic profile than etoposide

Confirmatory U.S. phase III trial of Scenesse begins

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...